Excellence in Peptide and Oligonucleotide Purification

This white paper discusses the advancements in peptide and oligonucleotide purification technologies, specifically focusing on GLP-1 receptor agonists. It outlines the therapeutic potential of peptides and oligonucleotides in treating various diseases, including metabolic disorders and cancers. The paper details the challenges faced in peptide therapy, such as rapid degradation and short in vivo half-life, and how recent advancements in peptide synthesis and manufacturing have addressed these issues. The authors present case studies that demonstrate the effectiveness of established technologies in optimizing purification processes for GLP-1 receptor agonists. Additionally, the paper highlights the growing market for peptide and oligonucleotide therapeutics, with a significant increase in FDA-approved drugs and a projected market growth. It emphasizes the role of contract development and manufacturing organizations (CDMOs) in supporting the development and production of these next-generation therapeutics, ensuring efficient manufacturing processes and high-quality outputs.